These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7579469)

  • 1. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
    Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC; Visser JJ; van Oostendorp WR; de Gast GC; Verdonck LF
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Leukocyte depletion and infection by cytomegalovirus].
    Mazeron MC
    Transfus Clin Biol; 2000 Jun; 7 Suppl 1():31s-35s. PubMed ID: 10919221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers MH; Mori M; Cays MJ; Meyers JD
    Blood; 1991 Jul; 78(1):246-50. PubMed ID: 1648976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion-transmitted cytomegalovirus infection.
    Bowden RA
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):155-66. PubMed ID: 7737939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
    Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
    Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of transfusion-transmitted cytomegalovirus infection.
    Pamphilon DH; Rider JR; Barbara JA; Williamson LM
    Transfus Med; 1999 Jun; 9(2):115-23. PubMed ID: 10354380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S; Gowland P; Eyer C; Widmer N; Abonnenc M; Prudent M; Masouridi-Levrat S; Duchosal MA; Niederhauser C
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
    Weisberg SP; Staley EM; Williams LA; Pham HP; Bachegowda LS; Cheng YH; Schwartz J; Shaz BH
    Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
    Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
    Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T; Schattenberg A; Van Dijk BA; Galama J; Olthuis H; Van der Meer JW; Kunst VA
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusion-associated cytomegalovirus infections.
    Adler SP
    Rev Infect Dis; 1983; 5(6):977-93. PubMed ID: 6318291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB; Lichtiger B
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
    Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
    Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group.
    Gilbert GL; Hayes K; Hudson IL; James J
    Lancet; 1989 Jun; 1(8649):1228-31. PubMed ID: 2566781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation.
    Bowden RA; Sayers M; Flournoy N; Newton B; Banaji M; Thomas ED; Meyers JD
    N Engl J Med; 1986 Apr; 314(16):1006-10. PubMed ID: 3007984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
    Nichols WG; Price TH; Gooley T; Corey L; Boeckh M
    Blood; 2003 May; 101(10):4195-200. PubMed ID: 12531791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
    Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustafsson-Jernberg A; Lewensohn-Fuchs I; Ringdén O
    Scand J Infect Dis; 2002; 34(5):347-50. PubMed ID: 12069017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.